| Document |
Document Title |
|
WO/2000/059874A1 |
The present application describes novel amides and derivatives thereof of formula (I) or pharmaceutically acceptable salt forms thereof, wherein these compounds are useful as inhibitors of matrix metalloproteinases, TNF-$g(a), and aggrec...
|
|
WO/2000/059861A1 |
Certain novel substituted (5,6)-dihydronaphthalenyl and substituted (5,6,7,8)-tetrahydronaphthalenyl compounds selectively activate Retinoid X Receptors (RXRs) and are useful in various dermatological diseases, in the treatment of malign...
|
|
WO/2000/059875A2 |
Derivatives of aryl and heterocyclic ureido and aryl and heterocyclic carboxamido phenoxy isobutyric acids have been found to inhibit the nonenzymatic glycation of proteins which often results in formation of advanced glycation endproduc...
|
|
WO/2000/059880A1 |
The present invention relates to cinnamide compounds of formula (I), in which at least one of R¿1? to R¿5? is a '$i(cis)-cinnamide' (a) or a '$i(trans)-cinnamide' (b) and the other variables are as defined in the claims, that are usefu...
|
|
WO/2000/059847A1 |
A process for the preparation of an $g(a)-hydroxy acid from an aqueous solution of an ammonium salt of an $g(a)-hydroxy acid which process comprises: (a) a first step of concentrating the aqueous solution such that the concentration of t...
|
|
WO/2000/059879A1 |
A method of preparing N,N-disubstituted-3,3'-dithiodipropionamide of formula (2) is provided. In the method, 3-mercaptopropionamide of formula (4) reacts with an aqueous solution of amine to prepare N-substituted-3-mercaptopropionamide o...
|
|
WO/2000/059831A2 |
The present invention provides a novel class of water-soluble cleavable surfactants and methods for utilizing these surfactants.
|
|
WO/2000/057872A1 |
(Z)-styryl benzylsulfones of formula (I) are useful as anticancer agents: wherein R¿1? is selected from the group consisting of hydrogen, chloro and nitro; R¿2? is selected from the group consisting of hydrogen, lower alkyl, lower alko...
|
|
WO/2000/058275A1 |
A water-soluble photosensitive compound which is represented by formula (1) or (2) and in which the photosensitive group gives an ultraviolet absorption spectrum having an absorption maximum wavelength of 305 nm or shorter; and a photose...
|
|
WO/2000/058293A2 |
The present invention relates to compounds of formula (I) wherein R?1¿, R?2¿, R?3¿ and R?4¿ are as defined in claim 1 and pharmaceutically acceptable salts thereof. The compounds are glucokinase activators which increase insulin secr...
|
|
WO/2000/058279A1 |
Compounds of formula (I) in which W is O, S, S(O) or S(O)¿2?; X is -SR4, -S(O)R4, or -S(O)¿2?R4, -S(O)¿2?NR5R6; or X is -C(O)NR5R6 provided that -C(O)NR5R6 is located at the 3', 4' or 5' position; Y is O or H¿2?; Z is hydrogen, halog...
|
|
WO/2000/056702A1 |
The present invention relates to the use of certain resorcinol derivatives as skin lightening agents.
|
|
WO/2000/056706A1 |
This invention relates generally to amino-thio-acrylonitriles of formula (Ia) or (Ib) as MEK inhibitors, pharmaceutical compositions containing the same, and methods of using the same as for treatment and prevention of inflammatory disor...
|
|
WO/2000/056707A1 |
The present invention relates to diaryl thioethers, including substituted diphenyl thioethers. Furthermore, the present invention relates to the use of the aforementioned compounds as ligands for cellular receptors, including adenosine a...
|
|
WO/2000/055128A1 |
Compounds of general formula (I), wherein R¿1? is H or C1 to C3 alkyl; R¿2? is aryl or -(CH¿2?)¿n?-aryl and n is 1 to 4; R¿3? is H or CH¿3?; and R¿4? is substituted or unsubstituted phenyl, pyridyl, thiophene, furan, indole, pyrro...
|
|
WO/2000/055127A1 |
Compounds represented by formula (I):as well as pharmaceutically acceptable salts, esters and hydrates thereof are disclosed along with pharmaceutical compositions and methods of treatment. The compounds are useful as inhibitors of caspa...
|
|
WO/2000/055126A2 |
The present invention relates to novel $i(N)-cyanomethyl amides which are cysteine protease inhibitors, the pharmaceutically acceptable salts and $i(N)-oxides thereof, their uses as therapeutic agents and the methods of their making.
|
|
WO/2000/055125A2 |
The present invention relates to novel N-cyanomethyl amides which are cysteine protease inhibitors, the pharmaceutically acceptable salts and N-oxides thereof, their uses as therapeutic agents and the methods of their making.
|
|
WO/2000/054756A2 |
Compounds and methods for mitigating neurodegeneration, effecting neuroprotection and/or effecting cognition enhancement in a subject are described. Neurological or cognitive conditions are treated by administering to a subject an effect...
|
|
WO/2000/053032A1 |
Feed additive for agro-zootechnical use, in particular for alimentary use in the zootechnical sector, consisting of a chelate obtained by the reaction of methionine hydroxy analogue with the carbonate of a bivalent metal. The reaction is...
|
|
WO/2000/053583A1 |
The present invention comprises small molecular weight, non-peptidic inhibitors of formula (I) of Protein Tyrosine Phosphatase 1 (PTP1) which are useful for the treatment and/or prevention of Non-Insulin Dependent Diabetes Mellitus (NIDDM).
|
|
WO/2000/053601A1 |
This invention provides new thiazolindinedione derivatives and new arylacetic acid derivatives. These compounds are useful for the treatment of cardiovascular diseases, certain endocrine diseases, certain inflammatory diseases, certain n...
|
|
WO/2000/053544A1 |
A process for producing a carboxylic acid derivative characterized by mixing a quaternary ammonium salt having a specific triazine ring in the molecule, a carboxylic acid compound, and a compound having a nucleophilic functional group to...
|
|
WO/2000/053172A1 |
CCR-3 receptor antagonists and novel methods for their use are provided.
|
|
WO/2000/053573A1 |
Novel compounds antagonistic to both of thromboxane A¿2? and prostaglandin D¿2? receptors and medicinal compositions containing the same. As the above compounds, compounds represented by general formula (I) are found out; wherein R?1¿...
|
|
WO/2000/051975A1 |
Disclosed are compounds which are inhibitors of metalloproteases and which are effective in treating conditions characterized by excess activity of these enzymes. In particular, the compounds have a structure according to Formula (I) whe...
|
|
WO/2000/051971A1 |
The present invention provides novel compounds of Formula (I) and prodrugs thereof, geometric and optical isomers thereof, and pharmaceutically acceptable salts of such compounds, prodrugs and isomers, wherein R?1¿ - R?8¿ and W are as ...
|
|
WO/2000/052530A1 |
Radically photopolymerizable compositions comprising (a) at least one ethylenically unsaturated photopolymerizable compound; (b) as photoinitiator, at least one compound of formulae (I, II, III, IV, V and/or VI), wherein m is 0 or 1; n i...
|
|
WO/2000/051972A1 |
The invention provides compounds of formula (I), wherein R?1¿ and R?2¿ independently represent H or C¿1-6? alkyl; R?3¿ represents phenyl substituted by at least one group selected form halo, CF¿3?, OCF¿3?, CN, OH, C¿1-6? alkyl and...
|
|
WO/2000/050392A1 |
2-Mercaptocarboxylic acid derivatives represented by general formula (I), pharmacologically acceptable esters of the same, or pharmacologically acceptable salts of both, which exhibit excellent antihyperglycemic and PPAR-activating effec...
|
|
WO/2000/050413A1 |
The invention relates to a process for preparing a benzothiazolone compound of formula (I), or a pharmaceutically acceptable salt or solvate thereof, wherein Ph represents a phenyl group, having pharmacological activity and to intermedia...
|
|
WO/2000/050398A2 |
The invention relates to compounds of general formula (I), wherein R is hydrogen, lower alkyl, lower alkoxy, halogen or trifluoromethyl; R?1¿ is hydrogen or halogen; or R and R?1¿ may be together -CH=CH-CH=CH-; R?2¿ is hydrogen, halog...
|
|
WO/2000/050377A1 |
A method for selective mono-N-alkylation of primary amines to produce secondary amines that are substantially free of overalkylated tertiary amines and quaternary ammonium salts, under mild reaction conditions without the necessity of pr...
|
|
WO/2000/050431A1 |
A compound which is a complex of formula (I) wherein each X, which may be the same or different, is hydrogen, alkyl, cycloalkyl, alkenyl, cycloalkenyl, alkynyl, aryl, heterocyclyl, aralkyl, alkaryl, acyl, halogen, haloalkyl, haloaryl, hy...
|
|
WO/2000/050380A1 |
The present invention relates to compounds that are a useful exhibit activity as serotonin, norepinephrine and dopamine reuptake inhibitors, and their pharmaceutically acceptable salts, and their use in the treatment of central nervous s...
|
|
WO/2000/050391A1 |
In accordance with the present invention, there is provided a novel class of sulfonamide compounds. Compounds of the invention contain a core sulfonamide group. Variable moieties connected to the sulfur atom and nitrogen atom of the sulf...
|
|
WO/2000/049008A1 |
A compound of formula (I), wherein R?1¿, R?2¿, R?3¿, AA?1¿, AA?2¿ and r are defined; a composition comprising a compound of formula (I) and a carrier or diluent; a compound of formula (I) for use as a medicament; the use of a compou...
|
|
WO/2000/048992A1 |
A compound of formula (I): wherein R?1¿, R?2¿, R?3¿ and Ar are defined; a composition comprising a compound of formula (I) and a carrier or diluent; a compound of formula (I) for use as a medicament; the use of a compound of formula (...
|
|
WO/2000/048988A1 |
Compounds of formula (1) and the pharmaceutically acceptable salts and esters thereof wherein X and Y are as defined in the specification, are effective inhibitors of the binding of VCAM-1 to VLA-4 $i(in vivo) and are useful in treating ...
|
|
WO1996012697A9 |
The present invention features compounds of general formulae a), b), c), able to modulate one or more activities of an inorganic ion receptor and methods for treating diseases or disorders by modulating inorganic ion receptor activity. P...
|
|
WO/2000/049007A1 |
A compound of formula (I) wherein Ar, R?1¿, R?2¿, R?3¿, R?4¿ and R?5¿ are defined; a composition comprising a compound of formula (I) and a carrier or diluent; a compound of formula (I) for use as a medicament, the use of a compound...
|
|
WO/2000/047031A2 |
The present invention is directed to partitioning agents and methods of using same to effectuate separation of a reactant, intermediate product, and/or final product from a reaction mixture while minimizing the need for traditional separ...
|
|
WO/2000/047548A1 |
Novel protein binding compounds of Formula (III): W-X-Y-(Z)¿n? in which Y is a branching moiety, Z represents a polydentate ligand chelating agent that coordinates a metal ion; X is a spacer moiety; n is an integer of at least 2 and W i...
|
|
WO/2000/047555A1 |
Disclosed is a composition of (1) a substituted benzaldehyde having general formula (I) where X is a leaving group in the ortho or para position, (2) a mercaptide having the general formula MSR' in an amount about stoichiometric to about...
|
|
WO1999063936A9 |
Novel multi-binding compounds (agents) which bind endothelin receptors are used to treat disorders affecting the cardiovascular, renal, endocrine and nervous systems in mammals that are mediated by the endothelin receptors, such as conge...
|
|
WO/2000/046184A1 |
The invention provides fungicidal compounds of formula (I) and salts thereof wherein: R?1¿ is alkyl, alkenyl, alkynyl, carbocyclyl or heterocyclyl, each of which may be substituted, or hydrogen; R?2¿ and R?3¿, which may be the same or...
|
|
WO/2000/046189A1 |
Sulfonamide derivatives having matrix metalloprotease inhibiting effects, which are compounds represented by general formula (I), optical isomers of the same, pharmaceutically acceptable salts of both, or hydrates of them: wherein A is a...
|
|
WO/2000/046190A1 |
A process for producing 2-hydroxy-4-methylthiobutanoic acid is provided wherein 2-hydroxy-4-methylthiobutyronitrile is converted to 2-hydroxy-4-methylthiobutanamide by using sulfuric acid, then adding an aqueous solution containing ammon...
|
|
WO/2000/044716A1 |
Compounds of formula (B): (1a), or (1b), (1c) are provided wherein the variables are as defined herein which are useful in disease conditions mediated by TNF-$g(a), such as rheumatoid arthritis, osteoarthritis, sepsis, AIDS, ulcerative c...
|
|
WO/2000/044715A1 |
Radioactive diagnostic drugs which comprise ?99m¿Tc metal complexes and exhibit high accumulation level for the heart to be excellent in heart imaging. The drugs contain as the active ingredients novel aralkylguanidine compounds represe...
|
